These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36738129)

  • 21. Facility variation and predictors of serum potassium monitoring after initiation of a mineralocorticoid receptor antagonist in patients with heart failure.
    Chauhan V; Dev S; Pham M; Lin S; Heidenreich P
    Am Heart J; 2015 Sep; 170(3):543-9. PubMed ID: 26385038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom.
    Linde C; Bakhai A; Furuland H; Evans M; McEwan P; Ayoubkhani D; Qin L
    J Am Heart Assoc; 2019 Nov; 8(22):e012655. PubMed ID: 31711387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality.
    Beusekamp JC; Tromp J; Cleland JGF; Givertz MM; Metra M; O'Connor CM; Teerlink JR; Ponikowski P; Ouwerkerk W; van Veldhuisen DJ; Voors AA; van der Meer P
    JACC Heart Fail; 2019 Nov; 7(11):970-979. PubMed ID: 31606364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist.
    Vardeny O; Claggett B; Anand I; Rossignol P; Desai AS; Zannad F; Pitt B; Solomon SD;
    Circ Heart Fail; 2014 Jul; 7(4):573-9. PubMed ID: 24812304
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016.
    Buysse JM; Huang IZ; Pitt B
    Future Cardiol; 2012 Jan; 8(1):17-28. PubMed ID: 22185443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial.
    Pitt B; Anker SD; Bushinsky DA; Kitzman DW; Zannad F; Huang IZ;
    Eur Heart J; 2011 Apr; 32(7):820-8. PubMed ID: 21208974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction.
    Ferreira JP; Butler J; Zannad F; Filippatos G; Schueler E; Steubl D; Zeller C; Januzzi JL; Pocock S; Packer M; Anker SD
    J Am Coll Cardiol; 2022 Mar; 79(12):1129-1137. PubMed ID: 35331406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.
    Butler J; Ezekowitz JA; Collins SP; Givertz MM; Teerlink JR; Walsh MN; Albert NM; Westlake Canary CA; Carson PE; Colvin-Adams M; Fang JC; Hernandez AF; Hershberger RE; Katz SD; Rogers JG; Spertus JA; Stevenson WG; Sweitzer NK; Tang WH; Stough WG; Starling RC
    J Card Fail; 2012 Apr; 18(4):265-81. PubMed ID: 22464767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mineralcorticoid Receptor Antagonist Withdrawal for Hyperkalemia and Mortality in Patients with Heart Failure.
    Lisi F; Parisi G; Gioia MI; Amato L; Bellino MC; Grande D; Massari F; Caldarola P; Ciccone MM; Iacoviello M
    Cardiorenal Med; 2020; 10(3):145-153. PubMed ID: 31982865
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High- Versus Low-dose Losartan and Serum Potassium: An Analysis From HEAAL.
    Ferreira JP; Konstam M; Rossignol P; Kiernan MS; Zannad F
    J Card Fail; 2023 Jan; 29(1):45-52. PubMed ID: 36244652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care.
    Trevisan M; Fu EL; Xu Y; Savarese G; Dekker FW; Lund LH; Clase CM; Sjölander A; Carrero JJ
    Eur J Heart Fail; 2021 Oct; 23(10):1698-1707. PubMed ID: 34196082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF.
    Ferreira JP; Rossignol P; Machu JL; Sharma A; Girerd N; Anker SD; Cleland JG; Dickstein K; Filippatos G; Hillege HL; Lang CC; Ter Maaten JM; Metra M; Ng L; Ponikowski P; Samani NJ; van Veldhuisen DJ; Zwinderman AH; Voors A; Zannad F
    Eur J Heart Fail; 2017 Oct; 19(10):1284-1293. PubMed ID: 28580625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN.
    Pitt B; Bakris GL; Weir MR; Freeman MW; Lainscak M; Mayo MR; Garza D; Zawadzki R; Berman L; Bushinsky DA
    ESC Heart Fail; 2018 Aug; 5(4):592-602. PubMed ID: 29767459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF.
    Shen L; Kristensen SL; Bengtsson O; Böhm M; de Boer RA; Docherty KF; Inzucchi SE; Katova T; Køber L; Kosiborod MN; Langkilde AM; Lindholm D; Martinez MFA; O'Meara E; Nicolau JC; Petrie MC; Ponikowski P; Sabatine MS; Schou M; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV
    JACC Heart Fail; 2021 Apr; 9(4):254-264. PubMed ID: 33549554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial.
    Desai AS; Liu J; Pfeffer MA; Claggett B; Fleg J; Lewis EF; McKinlay S; O'Meara E; Shah SJ; Sweitzer NK; Solomon S; Pitt B
    J Card Fail; 2018 May; 24(5):313-320. PubMed ID: 29572190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors.
    Pitt B; Bakris GL; Bushinsky DA; Garza D; Mayo MR; Stasiv Y; Christ-Schmidt H; Berman L; Weir MR
    Eur J Heart Fail; 2015 Oct; 17(10):1057-65. PubMed ID: 26459796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure.
    Butler J; Hernandez AF; Anstrom KJ; Kalogeropoulos A; Redfield MM; Konstam MA; Tang WH; Felker GM; Shah MR; Braunwald E
    JACC Heart Fail; 2016 Sep; 4(9):726-35. PubMed ID: 27522631
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mineralocorticoid Receptor Antagonists and Renal Outcomes in Heart Failure Patients with and without Chronic Kidney Disease.
    Mavrakanas TA; Giannetti N; Sapir-Pichhadze R; Alam A
    Cardiorenal Med; 2020; 10(1):32-41. PubMed ID: 31665724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities.
    Albert NM; Tyson RJ; Hill CL; DeVore AD; Spertus JA; Duffy C; Butler J; Patterson JH; Hernandez AF; Williams FB; Thomas L; Fonarow GC
    Am Heart J; 2021 May; 235():82-96. PubMed ID: 33497697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Experience with the potassium binder patiromer in hyperkalaemia management in heart failure patients in real life.
    Esteban-Fernández A; Ortiz Cortés C; López-Fernández S; Recio Mayoral A; Camacho Jurado FJ; Gómez Otero I; Molina M; Almenar Bonet L; López-Vilella R
    ESC Heart Fail; 2022 Oct; 9(5):3071-3078. PubMed ID: 35748119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.